Some Homo- and Heteropolynuclear Chelates

Liu, Chui Fan; Liu, C. H.

doi:10.1021/ic50015a016

Cited by 11 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The polynuclear structure similar to that proposed by Liu and Liu (38) for certain copper(I1) chelates of pyridine-2-aldoxime also corresponds t o the analytical results. However, if it may be assumed t h a t the stability of the species Cu(RHR)+ is greater than that of the polynuclear complex, the formation of Cu(RHR)+ as a n intermediate would be required.…”

Section: Copper C/zelates Potentiometric Studysupporting

confidence: 58%

The Copper(ii) Syn-Phenyl-2-Pyridyl Ketoxime System Part I

Meek¹,

Cheney²

1965

Can. J. Chem.

View full text Add to dashboard Cite

show abstract

Section: Copper C/zelates Potentiometric Studysupporting

confidence: 58%

The Copper(ii) Syn-Phenyl-2-Pyridyl Ketoxime System Part I

Meek¹,

Cheney²

1965

Can. J. Chem.

View full text Add to dashboard Cite

show abstract

“…Despite major efforts and detailed studies and predictions, none of platinum(IV) complexes, including JM216, has not been approved for clinical use. Very good results of biological tests of oxaliplatin and satraplatin encouraged the idea of synthesis of platinum(II) and platinum(IV) complex with edda type ligands as their analogues, in order to obtain better anti-cancer agents (42,43).…”

Section: Design and Biological Evolution Of Platinum Based Drugmentioning

confidence: 99%

“…Also satraplatin can be used for treatment of prostate, lung and ovarian tumors with little signs of nephro-, neuro-and ototoxicity. LA12 is a satraplatin analogue and future investigation will probably demonstrate that it may be used for ovarian carcinoma resistant on cisplatin, or even colorectal tumors (42,43). (Table 1).…”

Section: R 2 Eddatype Ligandmentioning

confidence: 99%

Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents

Jurišević

Radosavljević

Arsenijević

et al. 2016

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

show abstract

“…Even a minimal change in ligand structure significantly affects the antitumour capacity of synthesized compounds (6)(7). Lui was the first to synthesize platinum(IV) complexes with ethylenediamine-N,N'diacetate ligands (EDDA-type) (8). Platinum(IV) complexes with ethylenediamine-N,N-dicarboxylic acids and dialkyl esters exhibited an antitumour activity similar to that of cisplatin against several tumour cell lines (7,9).…”

mentioning

confidence: 99%

The Effects of Newly Synthesized Platinum(IV) Complexes on Cytotoxicity and Radiosensitization of Human Tumour CellsIn Vitro

et al. 2020

View full text Add to dashboard Cite

Aim: Newly synthesized platinum(IV) complexes with ethylenediamine-N,N'-diacetate ligands (EDDA-type) (butyl-Pt and pentyl-Pt) were investigated against two cancer (A549 lung, and HTB 140 melanoma) and one noncancerous (MRC-5 embryonic lung fibroblast) human cell lines. Materials and Methods: The effects of these agents were compared with those of cisplatin after 6-, 24-and 48-h treatment. Sulforhodamine-B (SRB) assay was performed to estimate the cytotoxic effect, while the inhibitory effect on cell proliferation was measured using 5-bromo-2,deoxyuridine (BrdU) incorporation assay. Cell cycle analysis was performed by flow cytometry. Type of cell death induced by these agents was determined by electrophoretic analysis of DNA, flow cytometry and by western blot analysis of proteins involved in induction of apoptosis. The effects of gamma irradiation, alone and in combination with platinumbased compounds, were examined by clonogenic and SRB assays. Results: All examined platinum-based compounds had inhibitory and antiproliferative effects on A549 cells, but not on HTB140 and MRC-5 cells. Butyl-Pt, pentyl-Pt and cisplatin arrested the cell cycle in the S-phase and induced apoptotic cell death via regulation of expression of B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) proteins. Platinum-based compounds increased the sensitivity of A549 cells to gamma irradiation. Butyl-Pt and pentyl-Pt showed better antitumour effects against A549 cells than did cisplatin, by interfering in cell proliferation and the cell cycle, and by triggering apoptosis. Conclusion: The effects of gamma irradiation on tumour cells may be amplified by pre-treatment of cells with platinum-based compounds.Cisplatin or cis-diamminedichloroplatinum(II) is an effective chemotherapeutic agent that is used in nearly 50% of all patients with cancer (1). It has been used in the fight against ovarian, head and neck, bladder, cervical, oesophageal, as well as against small-cell and non-small-cell lung cancer. The clinical utility of cisplatin is based on the inhibition of the processes that are important for growth and proliferation of cancer cells by binding to DNA molecules and preventing replication, transcription and cell-cycle progression, leading to tumour cell death (2, 3). However, cisplatin administration is associated with adverse effects and therapy resistance. The development of platinum analogues that have similar effectiveness as cisplatin but better toxicity profiles and lack cross-resistance is the major concern in research centres worldwide. Different modifications of cisplatin have been investigated to achieve this aim.Platinum complexes are widely used in cancer therapy research. Approximately 30 platinum(II) and platinum(IV) 5001

show abstract

Some Homo- and Heteropolynuclear Chelates

Cited by 11 publications

References 0 publications

The Copper(ii) Syn-Phenyl-2-Pyridyl Ketoxime System Part I

The Copper(ii) Syn-Phenyl-2-Pyridyl Ketoxime System Part I

Platinum Complexes with Edda (Ethylenediamine -N, N - Diacetate) Ligands as Potential Anticancer Agents

The Effects of Newly Synthesized Platinum(IV) Complexes on Cytotoxicity and Radiosensitization of Human Tumour CellsIn Vitro

Contact Info

Product

Resources

About